Moreover, ITGBL1 could activate the TGF-β/Smad pathway and its expression was transcriptionally suppressed by transcription factor JDP2, indicating that ITGBL1 may be a therapeutic target for the treatment of PC. This evidence concerns the gene JDP2 and pachyonychia congenita.